Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is pamidronate effective in preventing chemotherapy-induced bone loss?

Nature Clinical Practice Endocrinology & Metabolism volume 1, pages 78–79 (2005)Cite this article

boxed-textEl-Hajj Fuleihan G et al. (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90: 3209–3214

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Shapiro CL et al. (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306–3311

    Article  CAS  Google Scholar 

  2. Goodwin PJ et al. (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17: 2365–2370

    Article  CAS  Google Scholar 

  3. Shapiro CL et al. (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90: 41–46

    Article  CAS  Google Scholar 

  4. Shapiro CL (2005) Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 23: 4847–4849

    Article  CAS  Google Scholar 

  5. Lonning PE et al. (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23: 5126–5137

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine in the Division of Hematology and Oncology,

    Charles L Shapiro

  2. Director of Breast Medical Oncology at the Ohio State University Medical Center, Columbus, OH, USA

    Charles L Shapiro

Authors
  1. Charles L Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L Shapiro.

Ethics declarations

Competing interests

CLL Shapiro is a Consultant for Novartis and holds an Honorarium from Pfizer. He has research support from Sanofi-Aventis, Pfizer, Genentech, and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shapiro, C. Is pamidronate effective in preventing chemotherapy-induced bone loss?. Nat Rev Endocrinol 1, 78–79 (2005). https://doi.org/10.1038/ncpendmet0048

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0048

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing